Skip to main navigation
Main Corporate Nav
About Us
About Us
Board of Directors
Leadership
Partnering
Our History
Pipeline
Pipeline
Parkinson's Disease & Prasinezumab
ATTR Amyloidosis & PRX004
Alzheimer's Disease
Pioneering Neuroscience
Publications
Clinical Trials
Clinical Trials
Prasinezumab Phase 2 Study
PRX004 Phase 1 Study
Expanded Acces Policy
Investors
Investors
Press Releases
Events & Presentations
Financial & Filings
Corporate Governance
Stock information
Analyst Coverage
Careers
Careers
Our Values
Compensation & Benefits
Opportunities
Public House
Contact Us
Contact Us
About Us
Leadership
Board of Directors
Partnering
Our History
About Us
Management
Board of Directors
Partnering
Our History
Pipeline
Parkinson’s Disease & prasinezumab
ATTR Amyloidosis & PRX004
Alzheimer’s Disease
Neuroscience Discovery Programs
Publications
Clinical Trials
Prasinezumab Phase 2 Study
PRX004 Phase 1 Study
Expanded Access Policy
Investors
Press Releases
Events & Presentations
Financials & Filings
Corporate Governance
Stock Information
Analyst Coverage
Careers
Our Values
Compensation & Benefits
Opportunities
Public House
Contact Us
Menu
Menu
Event Details
Investor Relations
Overview
Press Releases
Events & Presentations
Financials & Filings
SEC Filings
Quarterly Results
Key Ratios
Irish Statutory Financial Statements
Corporate Governance
Committee Composition
Stock Information
Analyst Coverage
Shareholder Tools
Prothena Fourth Quarter 2013 Financial Results Conference Call
Mar 6, 2014
4:30 PM EST
Scroll to top